Abstract
Determination of serum free light chains (FLC) is established as standard for diagnosis and monitoring of multiple myeloma (MM) and other plasma cell dyscrasias. In 2014, the revised IMWG criteria implemented the serum free light chain ratio of involved FLC (iFLC) / non-involved FLC (niFLC) > 100 as a biomarker defining MM requiring treatment. This recommendation was based on Freelite assay, which relies on polyclonal antisera. Additionally, the monoclonal N-Latex FLC assay and more recently, the polyclonal Sebia FLC assay are available and approved for determination of FLC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
